Breaking News

Navin Fluorine International Launches Navin Molecular

New identity emphasizes broad experience in classical small-molecule chemical development and contract synthesis.

Navin Fluorine International Ltd., part of the Padmanabh Mafatlal Group, unveiled the new identity for its contract development and manufacturing (CDMO) division, Navin Molecular. The new brand aims to meet the emerging need for reliable, fast, and cost-effective custom synthesis and manufacturing services for the pharmaceutical and speciality chemicals industries.

In a statement, the company said that the new brand is being launched to showcase the broad platform that Navin Molecular can offer and will focus on two key value propositions.  First, to allow customers to build a geographically diverse supply chain that operates to internationally recognized standards for quality, safety, and the environment.  And second, to provide world-class facilities and strong expertise across the full range of complex chemistries that are required to manufacture advanced intermediates, including a range of extremely hazardous and challenging chemistries.

The rebranding is a key part of a customer-focused initiative to realign Navin Molecular’s diverse expertise under three core offerings: custom synthesis, contract manufacturing, and process and analytical development. The new identity emphasizes its broad experience in classical small-molecule chemical development and contract synthesis.

Rajendra Kumar Sahu, CEO of Navin Molecular said, “Since 2010 our CDMO division has been providing chemistry services which encompass a wide range of technologies.  And, whilst direct fluorination and other hazardous chemistries remain core competencies, we’ve been working hard to integrate the full range of our expertise into the portfolio.  The creation of the Navin Molecular brand is really the culmination of this work and, now that the rebrand is complete, we are very excited to share the details with our customers as we work towards being the partner of choice for the global pharmaceutical and speciality chemicals industry.”
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters